1-8 of 8
David I. Stirling
Close
Sort by
Journal Articles

Bioavailable Dual-Protein Degraders of CK1α and Transcriptional Kinase CDK9 As Potential Therapeutics for Hematological Malignancies

Leah Fung, PhD, Aparajita Hoskote Chourasia, PhD, Eduardo Torres, MSc, Imelda Lam, BSc, Paul Erdman, MSc, David Hecht, PhD, Robert Sullivan, PhD, Brooke McElwee, BSc, Normand Richard, MSc, Avanthika Venkatachalam, MSc, Irit Snir-Alkalay, PhD, Kyle WH Chan, PhD, Frank Mercurio, PhD, Yinon Ben-Neriah, MD PhD, David I Stirling, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4643.
https://doi.org/10.1182/blood-2019-131834
Published: 2019
Journal Articles

Targeting AML: The Development of Two Functionally and Mechanistically Distinct Classes of Cereblon-Mediated Protein Homeostatic Modulators

Aparajita Hoskote Chourasia, PhD, Leah Fung, PhD, Brooke McElwee, BSc, Normand Richard, MSc, Imelda Lam, BSc, Eduardo Torres, MSc, Paul Erdman, MSc, Robert Sullivan, PhD, David Hecht, PhD, Kyle WH Chan, PhD, Frank Mercurio, PhD, David I Stirling, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3361.
https://doi.org/10.1182/blood-2019-131872
Published: 2019
Journal Articles

Protein Homeostatic Modulators, a Novel Class of Cereblon-Targeting Small Molecules As Potential Clinical Candidates in Multiple Myeloma

Jianxuan Zou, PhD, Richard J. Jones, PhD, Janet E. Mertz, PhD, Hua Wang, PhD, Isere Kuiatse, PhD, Bob Sullivan, PhD, Leah Fung, PhD, Normand Richard, PhD, Paul Erdman, PhD, Eduardo Torres, PhD, Aparajita Hoskote Chourasia, PhD, Kyle WH Chan, PhD, Frank Mercurio, PhD, David I Stirling, PhD, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4418.
https://doi.org/10.1182/blood.V130.Suppl_1.4418.4418
Published: 2017
Journal Articles

Lenalidomide Displays Anti-Proliferative Activity and Combination Effects with Chemotherapeutic Agents Against a Burkitt’s Lymphoma Cell Line.

Anita K. Gandhi, PhD, Jian Kang, BS, Ling-Hua Zhang, PhD, Blake Bartlett, PhD, Peter H. Schafer, PhD, David I. Stirling, PhD
Journal: Blood
Blood (2007) 110 (11): 4516.
https://doi.org/10.1182/blood.V110.11.4516.4516
Published: 2007
Journal Articles

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

Noopur Raje, Shaji Kumar, Teru Hideshima, Kenji Ishitsuka, Dharminder Chauhan, Constantine Mitsiades, Klaus Podar, Steven Le Gouill, Paul Richardson, Nikhil C. Munshi, David I. Stirling, Joseph H. Antin, Kenneth C. Anderson
Journal: Blood
Blood (2004) 104 (13): 4188–4193.
https://doi.org/10.1182/blood-2004-06-2281
Published: 2004
Journal Articles

Combination of the mTOR Inhibitor Rapamycin and Revlimid™ (CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).

Noopur Raje, MD, Shaji Kumar, MD, Teru Hideshima, MD, PhD, Kenji Ishitsuka, MD, Dharminder Chauhan, PhD, Constantine Mitsiades, MD, PhD, Klaus Podar, PhD, Steven Le Gouill, MD, Paul Richardson, MD, Nikhil C. Munshi, MD, David I. Stirling, PhD, Joseph H. Antin, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2004) 104 (11): 1492.
https://doi.org/10.1182/blood.V104.11.1492.1492
Published: 2004
Journal Articles

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies, Noopur Raje, Teru Hideshima, Suzanne Lentzsch, Gloria Young, Yu-Tzu Tai, Boris Lin, Klaus Podar, Deepak Gupta, Dharminder Chauhan, Steven P. Treon, Paul G. Richardson, Robert L. Schlossman, Gareth J. Morgan, George W. Muller, David I. Stirling, Kenneth C. Anderson
Journal: Blood
Blood (2001) 98 (1): 210–216.
https://doi.org/10.1182/blood.V98.1.210
Published: 2001
Journal Articles

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Teru Hideshima, Dharminder Chauhan, Yoshihito Shima, Noopur Raje, Faith E. Davies, Yu-Tzu Tai, Steven P. Treon, Boris Lin, Robert L. Schlossman, Paul Richardson, George Muller, David I. Stirling, Kenneth C. Anderson
Journal: Blood
Blood (2000) 96 (9): 2943–2950.
https://doi.org/10.1182/blood.V96.9.2943
Published: 2000